Vera Therapeutics, Inc. Form 4 Filings

Vera Therapeutics, Inc. reported that its president and CEO, Marshall Fordyce, exercised options for 18,500 shares of Class A common stock on September 2, 2026 at an exercise price of $2.8968 per share and received the same number of shares. On the same date, he sold 18,500 shares at a weighted-average price of $35.1158 per share under a Rule 10b5-1 trading plan adopted on January 9, 2026. Following the option exercise, he held 507,301 shares subject to the exercised option grant.

Vera Therapeutics, Inc. president and CEO Marshall Fordyce exercised stock options covering 46,250 shares of Class A Common Stock on July 7, 2026 at an exercise price of $2.8968 per share, and on the same date sold 46,250 shares in multiple transactions at weighted-average prices between $40.7762 and $43.5947. The option, which vests over four years and expires on December 15, 2030, showed 525,801 derivative securities beneficially owned following the reported exercise. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on January 9, 2026.

Vera Therapeutics, Inc. President and CEO Marshall Fordyce reported option exercises and share sales in Class A Common Stock. On June 23, 2026, he exercised options for 18,500 shares at an exercise price of $2.8968 per share, increasing directly held common stock by the same amount. The related option position showed 572,051 derivative shares beneficially owned after the exercise. On the same date, he sold 18,412 shares at a weighted-average price of $37.9311 and an additional 88 shares at $38.43 per share. The sales were made pursuant to a written trading plan adopted on January 9, 2026 that meets Rule 10b5-1(c) requirements.

Vera Therapeutics, Inc. reported that President and CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock on May 12, 2026 at an exercise price of $2.8968 per share. The option exercise left 590,551 stock options outstanding under this award. On the same date, he sold 18,500 shares of Class A Common Stock in open-market transactions, including 14,219 shares at a weighted-average price of $36.6396 and 4,281 shares at a weighted-average price of $37.0868. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on January 9, 2026.

Boman Nancy Lee reported acquisition or exercise transactions in this Form 4 filing.

Vera Therapeutics, Inc. reported equity awards to Chief Regulatory Officer Nancy Lee Boman. On August 3, 2026 she received stock options over 63,011 Class A shares at $32.23 per share, expiring August 2, 2036, plus 44,987 RSUs under the 2024 Inducement Plan vesting from 2027 to 2030, each award subject to continuous service.

Vera Therapeutics, Inc. director and CEO Marshall Fordyce reported open-market sales of an aggregate 46,250 shares of Class A common stock on July 7, 2026. The shares were sold at weighted-average prices reflecting trade ranges from $40.39 to $43.97 per share.

The filing notes the sales were made under a written trading plan adopted on January 9, 2026 that meets Rule 10b5-1(c) requirements. Following these transactions, Fordyce holds 151,994 shares directly, plus 99,081 shares held by a trust and 122,949 shares held by a GRAT, both reported as indirect ownership.

Vera Therapeutics, Inc. director, president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A Common Stock on June 23, 2026. The sales were executed at weighted-average prices of $38.43 and $37.93 per share.

The filing states these transactions were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on January 9, 2026, with individual trades occurring between $37.43 and $38.315. After the sales, Fordyce directly holds 198,244 shares and indirectly holds 99,081 shares through a trust and 122,949 shares through a GRAT.

Vera Therapeutics director Scott W. Morrison received a grant of stock options covering 17,084 shares of Class A common stock. The options have an exercise price of $34.35 per share and vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, or sooner upon a change in control, subject to his continued service. After this grant, he holds options on 17,084 shares directly.

Vera Therapeutics director Andrew Cheng received a new stock option grant as part of his compensation. On the grant date, he was awarded options covering 17,084 shares of Class A Common Stock with an exercise price of $34.35 per share, all held directly.

The option vests in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided he remains in continuous service. It will also fully vest upon a change in control if he is still serving at that time. After this grant, he holds options for 17,084 shares, expiring in 2036.

Vera Therapeutics director Beth C. Seidenberg received a grant of stock options covering 17,084 shares of Class A common stock at an exercise price of $34.35 per share. The options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided she continues in service. They also fully vest if there is a change in control while she remains in service through that date.

Vera Therapeutics director Christy J. Oliger received a grant of stock options covering 17,084 shares of Class A common stock. The options have an exercise price of $34.35 per share and were granted as a compensation award, not a market purchase.

The options will vest in full on the earlier of the first anniversary of the grant date or the date of Vera Therapeutics' 2027 annual stockholder meeting, subject to Oliger’s continuous service. They will also fully vest upon a change in control if she remains in service through that date, and expire on May 20, 2036 if not exercised.

Vera Therapeutics, Inc. reported that director James R. Meyers received a stock option grant. The award covers options to buy 17,084 shares of Class A Common Stock at an exercise price of $34.35 per share, expiring on May 20, 2036.

The option vests in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual stockholder meeting, as long as Meyers remains in continuous service. It will also vest in full upon a change in control if he continues in service through that date.

Vera Therapeutics director Kimball Hall received a grant of stock options covering 17,084 shares of Class A common stock at an exercise price of $34.35 per share. These options expire on May 20, 2036 and are held directly.

The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided Hall remains in continuous service. They will also vest in full upon a change in control, again contingent on continuous service through that date.

Vera Therapeutics director Michael Morrissey received a grant of stock options covering 17,084 shares of Class A Common Stock. The options have a per-share exercise price of $34.35 and expire in 2036. They vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, with full vesting upon a change in control if he remains in service.

Vera Therapeutics director Patrick G. Enright received a stock option grant for 17,084 shares of Class A common stock. The option has an exercise price of $34.35 per share and expires on May 20, 2036. All 17,084 options were held directly after the grant.

The footnote states the option will vest in full on the earlier of the first anniversary of the grant date or the date of Vera Therapeutics' 2027 annual stockholder meeting, subject to continuous service. It will also vest in full upon a change in control if his service continues through that date.

Vera Therapeutics, Inc. president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A common stock on May 12, 2026. The shares were sold in two tranches of 4,281 shares at a weighted-average price of $37.0868 and 14,219 shares at a weighted-average price of $36.6396, with actual prices ranging from $35.96 to $37.15. These transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on January 9, 2026. The filing also reports indirect holdings through a trust and a GRAT, which together hold more than 200,000 shares after these transactions.

Vera Therapeutics, Inc. President and CEO Marshall Fordyce reported open‑market sales of Class A Common Stock on April 14, 2026. He sold 14,130 shares at an average price of $43.6649, 7,921 shares at $44.5784, and 900 shares at $45.5114, totaling 22,951 shares sold.

These transactions were executed pursuant to a pre‑arranged Rule 10b5‑1(c) trading plan adopted on January 9, 2026. Following the sales, Fordyce directly holds 235,244 shares. He also has indirect holdings of 122,949 shares through a GRAT and 99,081 shares through a trust, which together include 1,032 shares acquired under the company’s 2021 Employee Stock Purchase Plan on March 13, 2026.

Vera Therapeutics Chief Legal Officer Jane Wright-Mitchell received new equity awards. She was granted a stock option for 56,850 shares of Class A Common Stock at an exercise price of $40.73 per share, expiring on March 22, 2036.

She also received 42,403 restricted stock units under the 2024 Inducement Plan, representing 42,403 shares of Class A Common Stock. According to the vesting terms, one-fourth of the RSUs vest on each of May 20, 2027, 2028, 2029 and 2030, while the option vests 12/48ths on March 23, 2027 and 1/48th monthly thereafter, in each case contingent on continued service.

Vera Therapeutics, Inc. senior vice president of finance and chief accounting officer Joseph R. Young exercised stock options to acquire 10,000 shares of Class A common stock at an exercise price of $3.9396 per share on March 13, 2026.

Following the transactions, he directly owns 75,754 shares of Class A common stock and holds 38,589 stock options. The filing notes that 1,032 of his shares were acquired through the company’s 2021 Employee Stock Purchase Plan, and the option grant vests over time, with a portion vesting monthly.

Vera Therapeutics director receives stock option grant

Vera Therapeutics director Christopher Hite was granted an option to buy 24,937 shares of the company’s stock at an exercise price of $0.00 per share. The option vests monthly over three years, as long as he continues serving the company.

Vera Therapeutics, Inc. Chief Medical Officer Robert Brenner reported a mandated sale of 2,151 shares of Class A Common Stock on February 23, 2026, at a weighted-average price of $41.9839 per share. The sale was an open-market “sell-to-cover” transaction required to satisfy tax withholding obligations from the vesting of restricted stock units under the company’s equity incentive plans and is described as non-discretionary. The trading orders for these tax-related sales occurred over two business days, from February 23 to February 24, 2026. After this sale, Brenner held 50,947 shares of Vera Therapeutics common stock directly.

Vera Therapeutics SVP of Finance Joseph R. Young reported an open-market sale of 3,117 shares of Class A common stock on February 23, 2026, at a weighted-average price of $41.9839 per share. The shares were sold solely to cover tax withholding on vesting RSUs under a mandated sell-to-cover arrangement and were not a discretionary trade. After this transaction, Young directly held 64,722 shares.

Vera Therapeutics, Inc. chief financial officer Sean Grant reported an open‑market sale of 4,949 shares of Class A common stock at a weighted‑average price of $41.9839 per share. According to the disclosure, the transaction was a mandated sell‑to‑cover trade to satisfy tax withholding obligations from vesting restricted stock units rather than a discretionary sale.

After this transaction, Grant directly held 114,181 Vera Therapeutics shares and indirectly held 5,000 additional shares through a trust. The sale occurred as part of trading orders executed over two business days beginning on February 23, 2026 and ending on February 24, 2026.

Vera Therapeutics president and CEO Marshall Fordyce reported a mandated sale of 16,925 shares of Class A common stock. The shares were sold in open-market "sell-to-cover" transactions solely to satisfy tax withholding obligations tied to vesting restricted stock units.

The weighted-average sale price was $41.9839 per share, with individual trades executed between $41.005 and $42.84 over two business days beginning on February 23, 2026. After these sales, Fordyce directly holds 257,163 shares, with additional indirect holdings of 122,949 shares held by a GRAT and 99,081 shares held by a trust.

Vera Therapeutics Chief Operating Officer David Lee Johnson reported an open-market sale of 2,579 shares of Class A common stock at a weighted-average price of $41.9839 per share. After this transaction, he directly owned 45,727 shares.

According to the disclosure, the shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plans. The sale was mandated by the company’s sell-to-cover election and is described as not a discretionary trade by the executive.

Vera Therapeutics, Inc. Chief Regulatory Officer William D. Turner reported an open-market sale of 2,187 shares of Class A common stock at a weighted-average price of $41.9839 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations from vesting restricted stock units under the company’s equity incentive plans and did not represent a discretionary trade by Turner. The trades to satisfy withholding occurred over two business days, from February 23 to February 24, 2026. After these transactions, Turner beneficially owned 45,313 shares of Class A common stock.

Vera Therapeutics Chief Commercial Officer Laurence Matthew Skelton reported an open-market sale of 1,582 shares of Class A common stock. The shares were sold on February 23, 2026 at a weighted-average price of 41.9839 per share to satisfy tax withholding obligations from vesting restricted stock units.

The sale was executed under the company’s equity incentive plans as a mandated “sell-to-cover” transaction and was not a discretionary trade by Skelton. After this sale, he beneficially owned 64,218 shares of Vera Therapeutics Class A common stock.

Vera Therapeutics SVP of Finance and Chief Accounting Officer Joseph R. Young received new equity awards. On February 4, 2026, he was granted 10,000 shares of Class A Common Stock in the form of restricted stock units at $0 per share, bringing his directly held stock to 67,839 shares.

He was also granted stock options for 20,000 shares of Class A Common Stock at an exercise price of $42.74 per share, all held directly. The RSUs vest in four equal annual installments each February 20 from 2027 through 2030, while the options vest over 48 months starting March 4, 2026, subject to his continued service.

Vera Therapeutics President and CEO Fordyce Marshall reported new equity awards tied to continued service. On February 4, 2026, he received 68,800 RSUs of Class A common stock at no cost under the 2021 Equity Incentive Plan, vesting in four equal annual installments each February 20 from 2027 through 2030.

He was also granted a stock option for 137,500 shares of Class A common stock at an exercise price of $42.74 per share, with 1/48 vesting on March 4, 2026 and the remainder vesting monthly thereafter. Following these awards, Marshall reports 274,088 Class A shares held directly, plus indirect holdings of 122,949 shares through a GRAT and 99,081 shares through The Fordyce Revocable Trust.

Vera Therapeutics’ chief financial officer Sean Grant received new equity awards in the form of restricted stock units and stock options. On February 4, 2026, he was granted 25,000 RSUs tied to Class A Common Stock and a stock option for 50,000 shares at an exercise price of $42.74.

The RSUs vest in four equal annual installments on February 20 of 2027, 2028, 2029 and 2030, subject to continued service. The option vests over four years, beginning March 4, 2026, with monthly vesting thereafter, also conditioned on continued service. Following this grant, Grant directly holds 119,130 Class A shares plus 50,000 options, and 5,000 additional shares are held indirectly through a trust.

Vera Therapeutics Chief Commercial Officer Laurence Matthew Skelton reported new equity awards. On February 4, 2026, he received 20,000 shares of Class A Common Stock for $0, representing restricted stock units granted under Vera’s 2021 Equity Incentive Plan. After this award, he directly owned 65,800 Class A shares.

He was also granted a stock option for 40,000 shares of Class A Common Stock at an exercise price of $42.74 per share. One forty-eighth of the option vests on March 4, 2026, with the remainder vesting in equal monthly installments, while the RSUs vest in four equal annual installments each February 20 from 2027 through 2030, all subject to continued service.

Vera Therapeutics Chief Regulatory Officer receives new equity awards. William D. Turner was granted 25,000 restricted stock units (RSUs) of Class A Common Stock and a stock option covering 50,000 shares. The option has a $42.74 exercise price and was granted for no cash consideration.

One-fourth of the RSUs vest on each of February 20, 2027, 2028, 2029 and 2030, if he remains in service. The option vests in 48 equal monthly installments, starting March 4, 2026, also subject to continued service. After these grants, he directly holds 47,500 Class A shares and 50,000 options.

Vera Therapeutics Chief Operating Officer receives new equity awards. On February 4, 2026, David Lee Johnson was granted 20,000 restricted stock units of Class A Common Stock at a price of $0 under Vera’s 2021 Equity Incentive Plan and 40,000 stock options with an exercise price of $42.74.

The RSUs vest in four equal annual installments on February 20 of 2027, 2028, 2029 and 2030, assuming continued service. The stock options begin vesting on March 4, 2026, with 1/48th of the grant vesting monthly, also conditioned on continued service. Following the RSU grant, he beneficially owns 48,306 Class A shares directly.

Vera Therapeutics Chief Medical Officer granted RSUs and stock options

Vera Therapeutics’ Chief Medical Officer, Robert Brenner, reported equity awards dated February 4, 2026. He received 25,000 shares of Class A common stock in the form of restricted stock units, granted at $0 cost. These RSUs vest in four equal annual installments on February 20, 2027, 2028, 2029 and 2030, if he remains in continuous service.

He also received a stock option for 50,000 shares of Class A common stock at an exercise price of $42.74 per share, expiring on February 3, 2036. One forty‑eighth of the option vests on March 4, 2026, with the remainder vesting monthly thereafter, subject to continued service. After these transactions, Brenner directly beneficially owns 53,098 shares of Class A common stock.

Vera Therapeutics’ Chief Regulatory Officer reported an option exercise and share sale. On December 15, 2025, the officer exercised a stock option to buy 10,000 shares of Class A common stock at $15.53 per share, then sold 10,000 shares of Class A common stock in the open market at a weighted average price of $50.0767 per share under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. Following these transactions, the officer directly owned 22,500 shares of Class A common stock and held 245,000 stock options directly.

Vera Therapeutics, Inc. reported an insider share purchase by a director. On 12/11/2025, the reporting person bought 5,882 shares of Class A common stock at $42.5 per share and now directly holds 5,882 shares.

The filing also describes large indirect holdings through investment funds. Longitude Prime Fund, L.P. holds 1,797,619 shares and Longitude Venture Partners IV, L.P. holds 3,596,593 shares. The reporting person, related general partner entities and another managing member may be deemed to share voting and dispositive power over these fund-held shares, while each disclaims beneficial ownership except to the extent of their pecuniary interests.

Vera Therapeutics, Inc. (VERA) reported a stock option grant to a director on 11/25/2025. The filing shows a stock option to purchase 25,000 shares of Class A common stock at an exercise price of $29.43 per share, expiring on 11/24/2035.

The option will vest monthly over a three-year period, as long as the director continues to serve through each vesting date. The filing also states that all shares subject to the option will vest in full if there is a change in control, provided the director remains in continuous service through the date of that change in control.

Vera Therapeutics (VERA) Chief Legal Officer reports share sale. On 11/21/2025, the company’s Chief Legal Officer sold 3,864 shares of Class A common stock in a single reported transaction. The shares were sold at a weighted-average price of $27.8204, with individual trades executed between $27.19 and $28.035.

According to the disclosure, the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. After this transaction, the officer beneficially owns 49,136 shares of Vera Therapeutics common stock, held directly.

Vera Therapeutics (VERA) reported insider activity by its SVP, Finance and Chief Accounting Officer on a Form 4. The filing shows a sale of 15,000 Class A common shares on 11/11/2025 at a weighted-average price of $29.0583. The sale occurred across multiple trades between $29.03 and $29.17.

On 11/13/2025, the officer exercised 10,000 stock options at an exercise price of $3.9396, acquiring 10,000 Class A common shares. Following these transactions, the officer directly beneficially owned 57,839 shares. A related option grant covering the 10,000 shares vests with 1/4 on March 9, 2022 and 1/48 monthly thereafter. The share total includes 893 shares acquired under the company’s 2021 Employee Stock Purchase Plan.